#HeartHealth #HypertensionAwareness #PublicSafety
www.cbsnews.com
A police officer thought he had a muscle cramp. He ended up fighting for his life.
Kerry Breen is a news editor at CBSNews. com. A graduate of New York University's Arthur L. Carter School of Journalism, she previously worked at NBC News' TODAY Digital.
#Diabetes #Hypertension #CardiovascularHealth
www.medscape.com
Early Hypertension Linked to a Poorer Prognosis in T2D
In patients with type 2 diabetes (T2D), both young-onset hypertension (onset before the age of 45 years) and late-onset hypertension (onset at the age of 45 years or later) were associated with higher risks for cardiovascular disease (CVD), congestive heart failure, chronic kidney disease, and all-cause mortality, with young-onset hypertension linked to poorer outcomes.
#Diabetes #Hypertension #CardiovascularHealth
www.medscape.com
Early Hypertension Linked to a Poorer Prognosis in T2D
In patients with type 2 diabetes (T2D), both young-onset hypertension (onset before the age of 45 years) and late-onset hypertension (onset at the age of 45 years or later) were associated with higher risks for cardiovascular disease (CVD), congestive heart failure, chronic kidney disease, and all-cause mortality, with young-onset hypertension linked to poorer outcomes.
S
#Hypertension #Healthcare #Innovation
www.streetinsider.com
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
* Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.
S
#Hypertension #Healthcare #Innovation
www.streetinsider.com
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
* Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.
#Hypertension #HeartHealth #Pharmaceuticals
www.benzinga.com
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterIdorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.
#Hypertension #HeartHealth #Pharmaceuticals
www.benzinga.com
Idorsia's JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterIdorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.
